# Corvus Pharmaceuticals, Inc.: overview CRVS · Nasdaq · CIK 1626971 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crvs.md) · [Financials](/companies/crvs/financials.md) · [Filings](/companies/crvs/filings.md) · [Insiders](/companies/crvs/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.60)](/filings/0001104659-25-106259.md) | not reported | [(0.13)](/filings/0001104659-26-057100.md) | [(0.10)](/filings/0001104659-26-091975.md) | [(0.12)](/filings/0001104659-25-106259.md) | not reported | [(0.15)](/filings/0001104659-26-057100.md) | [(0.19)](/filings/0001104659-26-091975.md) | | Free cash flow | $m | not reported | not reported | [(8.3)](/filings/0001104659-26-057100.md) | [(5.9) d](/filings/0001104659-26-091975.md) | [(9.6) d](/filings/0001104659-25-106259.md) | [(9.2) d](/filings/0001104659-26-027047.md) | [(10.5)](/filings/0001104659-26-057100.md) | [(16.0) d](/filings/0001104659-26-091975.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.03)](/filings/0001558370-24-003567.md) | [(0.89)](/filings/0001558370-25-003621.md) | [(0.56)](/filings/0001104659-26-027047.md) | [(1.02)](/filings/0001104659-26-027047.md) | [(0.53)](/filings/0001104659-26-027047.md) | | Free cash flow | $m | [(36.7)](/filings/0001558370-24-003567.md) | [(27.3)](/filings/0001558370-25-003621.md) | [(24.0)](/filings/0001104659-26-027047.md) | not reported | [(33.0)](/filings/0001104659-26-027047.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crvs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $107.0m | 7,165,006 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $106.7m | 7,138,811 | | Added +978,389 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $66.8m | 4,474,091 | | Added +908,099 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $49.2m | 3,292,710 | | Added +58,172 | | [ADAMS STREET PARTNERS LLC](/funds/1193586.md) | 2026-06-30 | $48.9m | 3,275,616 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $41.9m | 2,805,816 | | Unchanged | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $40.8m | 2,731,632 | | Added +413,115 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $39.9m | 2,667,441 | | Added +375,000 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $37.2m | 2,491,939 | | Added +400 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $31.8m | 2,126,298 | | Added +373,500 | ## Recent filings [All 577 filings](/companies/crvs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 16:04 ET | [10-Q](/filings/0001104659-26-091975.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091975 | | 2026-08-06 | 16:02 ET | [8-K](/filings/0001171843-26-005317.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005317 | | 2026-07-22 | 16:02 ET | [8-K](/filings/0001104659-26-085790.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-085790 | | 2026-06-12 | 16:01 ET | [8-K](/filings/0001171843-26-004094.md) | 5.07 Shareholder vote results | 0001171843-26-004094 | | 2026-05-14 | 07:01 ET | [8-K](/filings/0001171843-26-003397.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-003397 | | 2026-05-07 | 16:05 ET | [10-Q](/filings/0001104659-26-057100.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057100 | | 2026-05-07 | 16:01 ET | [8-K](/filings/0001171843-26-003154.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003154 | | 2026-04-24 | 16:15 ET | [DEF 14A](/filings/0001104659-26-048595.md) | Proxy statement, period 2026-06-11 | 0001104659-26-048595 | | 2026-04-23 | 16:30 ET | [8-K](/filings/0001104659-26-047735.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-047735 | | 2026-03-13 | 08:46 ET | [8-K](/filings/0001104659-26-027390.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-027390 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-027047.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1626971 - Tickers: CRVS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.